A detailed history of Verus Capital Partners, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Verus Capital Partners, LLC holds 340 shares of REGN stock, worth $257,315. This represents 0.03% of its overall portfolio holdings.

Number of Shares
340
Previous 328 3.66%
Holding current value
$257,315
Previous $344,000 3.78%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$1024.09 - $1201.76 $12,289 - $14,421
12 Added 3.66%
340 $357,000
Q2 2024

Aug 01, 2024

BUY
$883.2 - $1071.19 $1,766 - $2,142
2 Added 0.61%
328 $344,000
Q1 2024

May 07, 2024

BUY
$902.69 - $993.35 $60,480 - $66,554
67 Added 25.87%
326 $313,000
Q4 2023

Feb 09, 2024

SELL
$775.18 - $881.7 $20,154 - $22,924
-26 Reduced 9.12%
259 $227,000
Q3 2023

Nov 01, 2023

SELL
$692.45 - $844.37 $3,462 - $4,221
-5 Reduced 1.72%
285 $234,000
Q2 2023

Jul 31, 2023

SELL
$700.03 - $830.35 $21,000 - $24,910
-30 Reduced 9.38%
290 $208,000
Q1 2023

May 09, 2023

BUY
$680.49 - $826.97 $217,756 - $264,630
320 New
320 $262,000
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $28,698 - $36,216
-50 Reduced 11.76%
375 $258,000
Q2 2022

Aug 09, 2022

SELL
$548.35 - $738.84 $74,027 - $99,743
-135 Reduced 24.11%
425 $252,000
Q1 2022

Aug 09, 2022

BUY
$595.12 - $698.43 $286,847 - $336,643
482 Added 617.95%
560 $364,000
Q1 2020

May 26, 2020

SELL
$336.18 - $494.43 $54,461 - $80,097
-162 Reduced 67.5%
78 $38,000
Q4 2019

Feb 27, 2020

BUY
$274.13 - $376.51 $65,791 - $90,362
240 New
240 $90,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Verus Capital Partners, LLC Portfolio

Follow Verus Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verus Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verus Capital Partners, LLC with notifications on news.